potency of BCG vaccines determined on animals.
Read Online

potency of BCG vaccines determined on animals.

  • 867 Want to read
  • ·
  • 67 Currently reading

Published in Copenhagen .
Written in English


  • BCG vaccines.

Book details:

LC ClassificationsQR189.5.T72 J47
The Physical Object
Pagination115 p.
Number of Pages115
ID Numbers
Open LibraryOL5022905M
LC Control Number76859261

Download potency of BCG vaccines determined on animals.


Introduction General considerations Special considerations Scope of the Recommendations BCG vaccine strains Potency-related tests Part A. Manufacturing recommendations A.1 Definitions A.2 General manufacturing recommendations A.3 Control of source materials A.4 Control of vaccine production A.5 Filling and containers   The vaccines, provided by the NICPB, were prepared by the Beijing, Shanghai, Lanzhou and Chanchun Institutes of Biological products. BCG-Copenhagen , obtained from the Statens Seruminstitut, Copenhagen, was included as a control vaccine of known potency in both animal models. The vaccines were suspended in 7H9 broth and stored at Cited by: The Mycobacterium bovis strain, bacille Calmette–Guérin (BCG) is one of the most widely used human vaccines and remains one of the safest vaccines available. It has been used in human populations for over 80 years and million children receive the vaccine annually. It has also been employed extensively for vaccine studies in laboratory animal hosts and is currently being developed for Cited by: Flynn's team tested several routes and doses of the only commercially available human TB vaccine, Bacille Calmette-Guérin (BCG), which is made of a live, weakened form of TB bacteria found in cattle.

  Laboratory animals also have been used to measure potency by showing that a given level of immune response (humoral) can be achieved (e.g., the use of guinea pigs to measure diphtheria or tetanus toxoid vaccine potency), and in a few cases, animal models have been developed to demonstrate protection against challenge (e.g., vaccines against. of animals. 3. Potency testing of BCG vaccines Viable count assay BCG vaccine contains live bacteria, though viable count is not in itself an assay of potency, it has been used as a surrogate of BCG potency. The cultural viable count assay, often known as Colony Forming Unit (CFU) test, is problematic and can present many problems for.   Historical studies of BCG. Studies of BCG vaccine in cattle were first reported by Calmette and Guérin and showed that relatively high doses of BCG (20 mg) could induce protection in cattle against experimental challenge with M. the studies of Calmette and Guérin (), intravenous challenge of control calves with virulent M. bovis resulted in severe generalised TB by 30–60 days.   Other non-routinely recommended live vaccines include adenovirus vaccine (used by the military), typhoid vaccine (Ty21a), and Calmette-Guerin (BCG). BCG is not used as a vaccine in the United States, but as a treatment for bladder cancer. Inactivated Vaccines. Inactivated vaccines are not live and cannot replicate.

  The potency of BCG vaccines determined on animals. Thesis, Copenhagen, 21 Youmans, G.P. and Youmans, A.S. The measurement of the re- sponse of immunized mice to infection with Mycobacterium tubercu- losis var. hominis.   Potency testing of BCG vaccine by modified ATP assay for viable count. The BCG vaccine is based on a live attenuated strain of Mycobacterium viability of organisms is essential for the stimulation of a protective immune response and monitoring viable counts is an integral part of quality control. vaccines to temperatures outside the recommended ranges can decrease their potency and reduce the effectiveness and protection they provide. Storage and handling errors can cost thousands of dollars in wasted vaccine and revaccination. Errors can also result in the loss of patient confidence when repeat doses are required. It is better to. BCG is a generic term representing a number of live tuberculosis vaccines, the original strain being the bacillus of Calmette and Guerin (BCG). Because each contemporary vaccine has been developed from a different strain of attenuated bovine bacilli, wide variation in resultant human immunity can be expected. BCG does not prevent the initial infection with Mycobacterium tuberculosis; however.